Anne-Mieke Vandamme

Anne-Mieke Vandamme, Stijn Imbrechts, Tulio de Oliveira, 2013, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Estimating an In Vivo Fitness Landscape During Protease and Reverse Transcriptase Treatment from Observed Genetic Evolution to Predict Accumulation of Mutations under Selective Pressure

Yves Moreau, Kristof Theys, Anne-Mieke Vandamme, 2007 .

Managing Resistance to Anti-HIV Drugs

Anne-Mieke Vandamme, A. Vandamme, E. Clercq, 1999, Drugs.

Genetic Variability and Molecular Evolution of the Human Respiratory Syncytial Virus Subgroup B Attachment G Protein

Anne-Mieke Vandamme, Philippe Lemey, Marc Van Ranst, 2005, Journal of Virology.

The impact of HIV-1 within-host evolution on transmission dynamics.

Ann Nowé, Kristof Theys, Anne-Mieke Vandamme, 2018, Current opinion in virology.

A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene.

Anne-Mieke Vandamme, Philippe Lemey, Yoeri Schrooten, 2005, Journal of virological methods.

Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors are subtype dependent

Lynn Morris, Anne-Mieke Vandamme, Praphan Phanuphak, 2004 .

Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006.

Anne-Mieke Vandamme, Katrien Fransen, Inge Derdelinckx, 2008, AIDS research and human retroviruses.

Investigation of Baseline Susceptibility to Protease Inhibitors in HIV-1 Subtypes C, F, G and Crf02_Ag

Anne-Mieke Vandamme, Koen Deforche, Ricardo Jorge Camacho, 2005, Antiviral therapy.

Edinburgh Research Explorer Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1

Anne-Mieke Vandamme, Paul Kellam, David Dunn, 2007 .

Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity

Anne-Mieke Vandamme, Paul Kellam, David Dunn, 2006, AIDS.

Limitations to contact tracing and phylogenetic analysis in establishing HIV type 1 transmission networks in Cuba.

Anne-Mieke Vandamme, Philippe Lemey, Sonia Resik, 2007, AIDS research and human retroviruses.

Hepatitis C Virus Evolutionary Patterns Studied Through Analysis of Full-Genome Sequences

Anne-Mieke Vandamme, Marco Salemi, M. Salemi, 2002, Journal of Molecular Evolution.

Functional conservation of HIV-1 Gag: implications for rational drug design

Kristof Theys, Anne-Mieke Vandamme, Guangdi Li, 2013, Retrovirology.

HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics

Klaus Korn, Kristof Theys, Anne-Mieke Vandamme, 2013, Retrovirology.

Correction: Antiretroviral Therapy Optimisation without Genotype Resistance Testing: A Perspective on Treatment History Based Models

Rolf Kaiser, Michal Rosen-Zvi, Anne-Mieke Vandamme, 2011, PLoS ONE.

Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update

Anne-Mieke Vandamme, Soo-Yon Rhee, Tommy F. Liu, 2009, PloS one.

The coalescent: population genetic inference using genealogies

Anne-Mieke Vandamme, Allen G. Rodrigo, Philippe Lemey, 2009 .

Mosaic Genomes of the Six Major Primate Lentivirus Lineages Revealed by Phylogenetic Analyses

Vincent Moulton, Anne-Mieke Vandamme, William M. Switzer, 2003, Journal of Virology.

The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes

Klaus Korn, Anne-Mieke Vandamme, Sabine Yerly, 2006, Journal of acquired immune deficiency syndromes.

Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration

Lynn Morris, Anne-Mieke Vandamme, Praphan Phanuphak, 2005, PLoS medicine.

No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs.

Anne-Mieke Vandamme, Yoeri Schrooten, Kristel Van Laethem, 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Science in court: the myth of HIV fingerprinting.

Anne-Mieke Vandamme, Jan Albert, L. Power, 2011, The Lancet. Infectious diseases.

Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response

Rolf Kaiser, Anne-Mieke Vandamme, Stijn Imbrechts, 2013, PloS one.

Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.

Klaus Korn, Anne-Mieke Vandamme, Sabine Yerly, 2005, The Journal of infectious diseases.

The demise of multidrug-resistant HIV-1: the national time trend in Portugal

Kristof Theys, Anne-Mieke Vandamme, Francisco Antunes, 2012, The Journal of antimicrobial chemotherapy.

U.S. Human Immunodeficiency Virus Type 1 Epidemic: Date of Origin, Population History, and Characterization of Early Strains

Anne-Mieke Vandamme, Philippe Lemey, Oliver G. Pybus, 2003, Journal of Virology.

Modelled in vivo HIV Fitness under drug Selective Pressure and Estimated Genetic Barrier Towards Resistance are Predictive for Virological Response

Yves Moreau, Kristof Theys, Anne-Mieke Vandamme, 2008, Antiviral therapy.

A prospect on the use of antiviral drugs to control local outbreaks of COVID-19

Anne-Mieke Vandamme, Niel Hens, Andrea Torneri, 2020, BMC Medicine.

Antiretroviral resistance in different HIV-1 subtypes: impact on therapy outcomes and resistance testing interpretation

Anne-Mieke Vandamme, A. Vandamme, R. Camacho, 2007, Current opinion in HIV and AIDS.

A new ensemble coevolution system for detecting HIV-1 protein coevolution

Jan Ramon, Kristof Theys, Anne-Mieke Vandamme, 2015, Biology Direct.

A computational method for the identification of Dengue, Zika and Chikungunya virus species and genotypes

Ann Nowé, Kristof Theys, Anne-Mieke Vandamme, 2019, PLoS neglected tropical diseases.

Molecular Evolution and Circulation Patterns of Human Respiratory Syncytial Virus Subgroup A: Positively Selected Sites in the Attachment G Glycoprotein

Anne-Mieke Vandamme, Philippe Lemey, Marc Van Ranst, 2004, Journal of Virology.

Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.

Anne-Mieke Vandamme, Koen Deforche, Kristel Van Laethem, 2008, The Journal of antimicrobial chemotherapy.

Zika genomics urgently need standardized and curated reference sequences

Kristof Theys, Anne-Mieke Vandamme, Lize Cuypers, 2017, PLoS pathogens.

Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development

Kristof Theys, Anne-Mieke Vandamme, Lize Cuypers, 2016, Virus evolution.

The Phylogenetic Handbook: A Practical Approach to Phylogenetic Analysis and Hypothesis Testing

Anne-Mieke Vandamme, Philippe Lemey, Marco Salemi, 2009 .

Mapping Sites of Positive Selection and Amino Acid Diversification in the HIV Genome

Anne-Mieke Vandamme, Tulio de Oliveira, Marco Salemi, 2004, Genetics.

Prevalence and origin of HIV-1 group M subtypes among patients attending a Belgian hospital in 1999.

Anne-Mieke Vandamme, Inge Derdelinckx, Joke Snoeck, 2002, Virus research.

Recombination Confounds the Early Evolutionary History of Human Immunodeficiency Virus Type 1: Subtype G Is a Circulating Recombinant Form

Anne-Mieke Vandamme, Andrew Rambaut, Philippe Lemey, 2007, Journal of Virology.

Tracing the origin and history of the HIV-2 epidemic

Anne-Mieke Vandamme, Philippe Lemey, Marco Salemi, 2003, Proceedings of the National Academy of Sciences of the United States of America.